Beyond the PD-1/CTLA-4 axis, efforts are directed toward characterizing additional immune checkpoints such as LAG-3 and optimizing CTLA-4 blockade to improve therapeutic efficacy in CRC, especially in CD8+ T cell. This evidence concerns the gene CD8A and colorectal carcinoma.